Constant's lead drug candidate, TXA127, is a pharmaceutical formulation of the natural human peptide, angiotensin-(1-7) [Ang-(1-7)].
Ang-(1-7), the active ingredient in Constant’s product, TXA127, has been shown to have multiple biologic effects:
-stimulating endothelial progenitor cells
-stimulating muscle satellite cells
-stimulating oligodendrocyte progenitor cells
-reducing oxidative stress and ROS,
-restoring the integrity of epithelial and endothelial surfaces,
-reducing inflammation by reversing the increased permeability of the blood vessels caused by the virus; thereby preventing movement of inflammatory cells into tissue leading to the “cytokine storm,”
-reducing apoptosis,
-inhibiting coagulopathy, and
-reducing fibrosis through down-regulation of the TGF beta pathway.
Ang-(1-7) has been shown to have positive outcomes in a number of animal models of stroke, heart disease, and muscle dystrophies. In addition, in several disease models it has become clear that blocking the effect of Ang-(1-7) is detrimental.
Company Details
- Employees
- 1
- Address
- 303 Congress St, Boston,ma 02210,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Boston, MA
Constant Therapeutics Questions
Constant Therapeutics's website is https://www.constanttherapeutics.com
Constant Therapeutics's LinkedIn profile is https://www.linkedin.com/company/constant-therapeutics
Constant Therapeutics has
1 employees.
View email and phone details for 1
employees at Constant Therapeutics.
Constant Therapeutics's industry is
Biotechnology Research
Constant Therapeutics's top competitors are
Angio-Proteomie,
Captivate Bio,
Insideoutbio,
Arp American Research Products, Inc.,
Ab Biosciences,
Alphabioregen, Inc.,
Medinect Ophtho,
Kbdna,
Larmorbio,
Mzbio, Inc.
Constant Therapeutics's categories are Biotechnology Research
